Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 25;43(1):329–341. doi: 10.1007/s11357-020-00286-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — The SR model suggests that senolytic treatment starting at old age can have a large effect even if given infrequently. a Average senescent cell abundance trajectories with recurrent treatment with senolytics (gray dashed) and without (black). The senolytic is applied once every 60 days, starting from age 70 years, and each dose removes about half of the senescent cells present. The recurrent treatment with senolytics reduces senescent cell levels, which then re-accumulate until the next treatment (Inset). This re-accumulation takes longer the longer the senescent cell half-life. b The effectiveness of senolytic treatment starting at age 70 as a function of senolytic dose (fraction of senescent cells killed) and interval between treatments. Effectiveness is measured as number of years in which the senescent load at age 80 is shifted to levels typical at younger ages due to the treatment. Trajectories were simulated using the SR model with human parameters (see “Materials and methods” section), assuming that senolytics are effective against a susceptible subpopulation of senescent cells which consists of 25% of the senescent cells.